Off-pump myocardial revascularization attenuates endothelin-1 expression in systemic, pulmonary, and coronary circulation

What Was Tested

Researchers studied Endothelin-1 in this randomized controlled trial publication.

The objective of this study was to evaluate the influence of cardiopulmonary bypass (CPB) on endothelin-1 (ET-1) expression in various circulation compartments in patients undergoing myocardial revascularization.

Who Took Part

The abstract describes 30 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

A total of 30 patients were randomized to undergo myocardial revascularization with (CABG, n = 15) or without (OPCAB, n = 15) CPB.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Endothelin-1 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Samples were taken preoperatively, after establishing CPB and after CPB (CABG group), prior to and after revascularization (OPCAB group), and 6 and 24 h postoperatively.

Values of ET-1 were compared between groups at all time points and correlated with postoperative cardioselective enzyme values and clinical parameters.

What Was Measured

The subject headings attached to it are Biomarkers, Coronary Artery Bypass, Off-Pump, Coronary Artery Disease, Coronary Circulation, Coronary Vessels, Endothelin-1 and Myocardial Revascularization.

What This Means in Plain Language

The paper is a randomized study of Endothelin-1 in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Wiener klinische Wochenschrift), a journal based in Austria.

More context: the Endothelin-1 compound page, all human trials.